Source 1primary paper2025MED
Toolkit/virus-like particles
virus-like particles
Also known as: genome-editing VLPs, VLPs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Subsequently, we delve into cutting-edge applications of nanoparticles to enhance immune protection, including mosaic and cocktail nanoparticle vaccines, surface-modified targeting strategies, and the integration of mRNA technology with virus-like particles (VLPs).
Usefulness & Problems
Why this is useful
Virus-like particles are self-assembled nanostructures made from viral structural proteins that mimic native virions without carrying genetic material. In this review they are presented as biomimetic delivery platforms for vaccines and therapeutics.; vaccine development; therapeutic development; eliciting humoral immune responses; eliciting cellular immune responses; Virus-like particles are discussed as emerging delivery vehicles for gene editing therapies in cardiovascular disease.; delivery of gene editing payloads; Virus-like particles are presented as a proteinaceous scaffold class relevant to enzyme immobilization. In the review framing, they are part of the broader toolkit for organizing enzymes in structured assemblies.; proteinaceous scaffold design for enzyme immobilization; enzyme spatial organization; VLPs are presented as an FMD vaccine platform and advanced delivery method associated with enhanced immune responses. In the meta-analysis summary, they showed relatively higher protection than other reviewed platforms.; foot-and-mouth disease vaccine platform design; enhancing immune responses; VLPs are used as delivery vehicles to introduce genes, transcripts, or proteins into cells. In this paper they are positioned as a preferred platform for genome editing because they can deliver low doses of heterologous proteins and nucleic acids.; intracellular delivery of genes, transcripts, or proteins; genome editing applications requiring low doses of heterologous proteins and nucleic acids; Virus-like particles are presented as one of the nanotechnology-enabled platforms used in COVID-19 treatment efforts. The abstract treats them as a platform class rather than detailing a specific construct.; COVID-19 treatment efforts; nanoparticle-enabled vaccine or therapeutic platform discussions; Virus-like particles are named as a delivery innovation discussed in the review for mRNA vaccine design and translation.; mRNA vaccine delivery; Virus-like particles are included as a delivery platform within the review's gene therapy delivery landscape.; delivery of gene therapy payloads; Virus-like particles are named as a biological nanoparticle class relevant to CAR therapy delivery challenges. The abstract groups them with exosomes and biomimetic nanostructures as potentially useful platforms.; addressing delivery and safety limitations in CAR therapy; Virus-like particles are presented as a platform integrated with mRNA technology within nanoparticle-enabled broad-spectrum vaccine strategies.; integration with mRNA technology in broad-spectrum vaccine approaches; nanoparticle-enabled enhancement of immune protection
Source:
Virus-like particles are self-assembled nanostructures made from viral structural proteins that mimic native virions without carrying genetic material. In this review they are presented as biomimetic delivery platforms for vaccines and therapeutics.
Source:
vaccine development
Source:
therapeutic development
Source:
eliciting humoral immune responses
Source:
eliciting cellular immune responses
Source:
Virus-like particles are discussed as emerging delivery vehicles for gene editing therapies in cardiovascular disease.
Source:
delivery of gene editing payloads
Source:
Virus-like particles are presented as a proteinaceous scaffold class relevant to enzyme immobilization. In the review framing, they are part of the broader toolkit for organizing enzymes in structured assemblies.
Source:
proteinaceous scaffold design for enzyme immobilization
Source:
enzyme spatial organization
Source:
VLPs are presented as an FMD vaccine platform and advanced delivery method associated with enhanced immune responses. In the meta-analysis summary, they showed relatively higher protection than other reviewed platforms.
Source:
foot-and-mouth disease vaccine platform design
Source:
enhancing immune responses
Source:
VLPs are used as delivery vehicles to introduce genes, transcripts, or proteins into cells. In this paper they are positioned as a preferred platform for genome editing because they can deliver low doses of heterologous proteins and nucleic acids.
Source:
intracellular delivery of genes, transcripts, or proteins
Source:
genome editing applications requiring low doses of heterologous proteins and nucleic acids
Source:
Virus-like particles are presented as one of the nanotechnology-enabled platforms used in COVID-19 treatment efforts. The abstract treats them as a platform class rather than detailing a specific construct.
Source:
COVID-19 treatment efforts
Source:
nanoparticle-enabled vaccine or therapeutic platform discussions
Source:
Virus-like particles are named as a delivery innovation discussed in the review for mRNA vaccine design and translation.
Source:
mRNA vaccine delivery
Source:
Virus-like particles are included as a delivery platform within the review's gene therapy delivery landscape.
Source:
delivery of gene therapy payloads
Source:
Virus-like particles are named as a biological nanoparticle class relevant to CAR therapy delivery challenges. The abstract groups them with exosomes and biomimetic nanostructures as potentially useful platforms.
Source:
addressing delivery and safety limitations in CAR therapy
Source:
Virus-like particles are presented as a platform integrated with mRNA technology within nanoparticle-enabled broad-spectrum vaccine strategies.
Source:
integration with mRNA technology in broad-spectrum vaccine approaches
Source:
nanoparticle-enabled enhancement of immune protection
Problem solved
VLPs provide viral architectural mimicry and strong immunogenicity while eliminating the risk of replication. This addresses the need for vaccine technologies that are safe, effective, and scalable.; providing virus-mimicking immunogenic platforms without genetic material; reducing replication risk while preserving viral architectural mimicry; They address the need to deliver gene editing systems in vivo.; provides a delivery vehicle for in vivo gene editing applications; They are included as advanced scaffold options for enzyme organization beyond conventional carrier materials.; providing structured protein-based compartments or assemblies for enzyme organization; The review frames VLPs as a way to improve protective vaccine performance against FMD. They are highlighted as part of advanced delivery strategies intended to strengthen immune responses.; providing an advanced vaccine platform associated with higher protective effectiveness than some compared platforms; They solve the problem of getting therapeutic molecular cargo into cells with strong cell-entry capacity. This is especially relevant when low-dose delivery of programmable editors is needed.; providing robust cell entry for therapeutic molecular cargo delivery; They expand the set of nanoparticle-related platform options for COVID-19 intervention design.; provides a nanoparticle-related platform class for treatment-oriented COVID-19 interventions; They are presented as a possible platform for mRNA vaccine delivery.; providing a delivery platform for mRNA vaccines; They provide another route for transporting therapeutic editing components.; adds an alternative delivery platform within the gene therapy toolkit; They are presented as part of the set of biological nanoparticles that may address delivery-related limitations in CAR therapy.; limitations associated with genetic material delivery; The review frames VLP-linked nanoparticle approaches as a way to enhance immune protection for broad-spectrum vaccines.; supports delivery-platform strategies discussed for broad-spectrum vaccine innovation
Source:
VLPs provide viral architectural mimicry and strong immunogenicity while eliminating the risk of replication. This addresses the need for vaccine technologies that are safe, effective, and scalable.
Source:
providing virus-mimicking immunogenic platforms without genetic material
Source:
reducing replication risk while preserving viral architectural mimicry
Source:
They address the need to deliver gene editing systems in vivo.
Source:
provides a delivery vehicle for in vivo gene editing applications
Source:
They are included as advanced scaffold options for enzyme organization beyond conventional carrier materials.
Source:
providing structured protein-based compartments or assemblies for enzyme organization
Source:
The review frames VLPs as a way to improve protective vaccine performance against FMD. They are highlighted as part of advanced delivery strategies intended to strengthen immune responses.
Source:
providing an advanced vaccine platform associated with higher protective effectiveness than some compared platforms
Source:
They solve the problem of getting therapeutic molecular cargo into cells with strong cell-entry capacity. This is especially relevant when low-dose delivery of programmable editors is needed.
Source:
providing robust cell entry for therapeutic molecular cargo delivery
Source:
They expand the set of nanoparticle-related platform options for COVID-19 intervention design.
Source:
provides a nanoparticle-related platform class for treatment-oriented COVID-19 interventions
Source:
They are presented as a possible platform for mRNA vaccine delivery.
Source:
providing a delivery platform for mRNA vaccines
Source:
They provide another route for transporting therapeutic editing components.
Source:
adds an alternative delivery platform within the gene therapy toolkit
Source:
They are presented as part of the set of biological nanoparticles that may address delivery-related limitations in CAR therapy.
Source:
limitations associated with genetic material delivery
Source:
The review frames VLP-linked nanoparticle approaches as a way to enhance immune protection for broad-spectrum vaccines.
Source:
supports delivery-platform strategies discussed for broad-spectrum vaccine innovation
Problem links
The item summary explicitly mentions nanoparticle vaccines and immune protection, so VLPs could plausibly support development of prophylactic tools that lower infection and transmission. This is relevant to the gap at a broad level, but the supplied evidence does not connect VLPs to airborne, surface, PPE, or environmental transmission control specifically.
adds an alternative delivery platform within the gene therapy toolkit
LiteratureThey provide another route for transporting therapeutic editing components.
Source:
They provide another route for transporting therapeutic editing components.
limitations associated with genetic material delivery
LiteratureThey are presented as part of the set of biological nanoparticles that may address delivery-related limitations in CAR therapy.
Source:
They are presented as part of the set of biological nanoparticles that may address delivery-related limitations in CAR therapy.
provides a delivery vehicle for in vivo gene editing applications
LiteratureThey address the need to deliver gene editing systems in vivo.
Source:
They address the need to deliver gene editing systems in vivo.
provides a nanoparticle-related platform class for treatment-oriented COVID-19 interventions
LiteratureThey expand the set of nanoparticle-related platform options for COVID-19 intervention design.
Source:
They expand the set of nanoparticle-related platform options for COVID-19 intervention design.
providing a delivery platform for mRNA vaccines
LiteratureThey are presented as a possible platform for mRNA vaccine delivery.
Source:
They are presented as a possible platform for mRNA vaccine delivery.
providing an advanced vaccine platform associated with higher protective effectiveness than some compared platforms
LiteratureThe review frames VLPs as a way to improve protective vaccine performance against FMD. They are highlighted as part of advanced delivery strategies intended to strengthen immune responses.
Source:
The review frames VLPs as a way to improve protective vaccine performance against FMD. They are highlighted as part of advanced delivery strategies intended to strengthen immune responses.
providing robust cell entry for therapeutic molecular cargo delivery
LiteratureThey solve the problem of getting therapeutic molecular cargo into cells with strong cell-entry capacity. This is especially relevant when low-dose delivery of programmable editors is needed.
Source:
They solve the problem of getting therapeutic molecular cargo into cells with strong cell-entry capacity. This is especially relevant when low-dose delivery of programmable editors is needed.
providing structured protein-based compartments or assemblies for enzyme organization
LiteratureThey are included as advanced scaffold options for enzyme organization beyond conventional carrier materials.
Source:
They are included as advanced scaffold options for enzyme organization beyond conventional carrier materials.
providing virus-mimicking immunogenic platforms without genetic material
LiteratureVLPs provide viral architectural mimicry and strong immunogenicity while eliminating the risk of replication. This addresses the need for vaccine technologies that are safe, effective, and scalable.
Source:
VLPs provide viral architectural mimicry and strong immunogenicity while eliminating the risk of replication. This addresses the need for vaccine technologies that are safe, effective, and scalable.
reducing replication risk while preserving viral architectural mimicry
LiteratureVLPs provide viral architectural mimicry and strong immunogenicity while eliminating the risk of replication. This addresses the need for vaccine technologies that are safe, effective, and scalable.
Source:
VLPs provide viral architectural mimicry and strong immunogenicity while eliminating the risk of replication. This addresses the need for vaccine technologies that are safe, effective, and scalable.
supports delivery-platform strategies discussed for broad-spectrum vaccine innovation
LiteratureThe review frames VLP-linked nanoparticle approaches as a way to enhance immune protection for broad-spectrum vaccines.
Source:
The review frames VLP-linked nanoparticle approaches as a way to enhance immune protection for broad-spectrum vaccines.
Published Workflows
Objective: Progress from conventional immobilization supports to more advanced protein-based scaffold systems that enable programmable enzyme colocalization, metabolite channeling, and pathway-level control.
Why it works: The review's tiered logic moves from established supports that address stability, reuse, and process issues toward protein-based and compartmentalized systems that add programmable spatial organization and pathway control.
enzyme colocalizationmetabolite channelingcompartmentalizationselective permeabilityenzyme immobilizationprotein scaffold engineeringorthogonal shell engineeringmodular cargo recruitment
Stages
- 1.Naturally derived biopolymer supports(library_design)
This stage represents the established baseline of enzyme immobilization approaches before moving to more programmable scaffold systems.
Selection: Use established immobilization carriers for enhancing biocatalyst performance and addressing stability, reuse, and apparent reaction efficiency through biochemical engineering strategies.
- 2.Engineered protein scaffolds(functional_characterization)
This stage introduces advanced scaffold architectures that improve spatial organization and control for multi-enzyme systems.
Selection: Adopt proteinaceous scaffolds when programmable enzyme colocalization and metabolite channeling are needed beyond what traditional carriers provide.
- 3.Bacterial microcompartments as emerging organelle-like platforms(confirmatory_validation)
BMCs are highlighted as the most advanced scaffold class in the review's tiered perspective because they add compartment-like control features beyond general protein scaffolds.
Selection: Prioritize BMCs when spatial precision, selective permeability, and encapsulation of multi-enzyme pathways are desired for pathway design and metabolic control.
Objective: Develop a scalable, broadly applicable purification workflow for genome-editing VLPs that improves purity, integrity, biological activity, and therapeutic efficacy.
Why it works: The workflow was developed around characteristic properties of MLV-derived engineered VLPs and HIV-derived engineered nucleocytosolic vehicles, and uses chromatographic steps to deplete contaminants while improving VLP integrity and biological activity.
removal of host cell proteinsremoval of cell-culture contaminantspreservation or improvement of VLP integritysingle-modal chromatographymultimodal chromatographymass spectrometric analysisin vivo evaluation
Stages
- 1.Single-modal chromatographic purification(secondary_characterization)
This stage is part of the developed purification workflow intended to improve product quality over ultracentrifugation-based methods.
Selection: chromatographic purification of genome-editing VLPs based on their characteristic properties
- 2.Multimodal chromatographic purification(secondary_characterization)
This stage contributes to the scalable purification platform that yields higher-quality VLPs than conventional ultracentrifugation.
Selection: further chromatographic purification to remove contaminants and improve final VLP quality
- 3.Mass spectrometric composition analysis(confirmatory_validation)
This stage confirms that the purification workflow substantially decreases contaminants and enriches VLP-specific proteins.
Selection: assessment of contaminant reduction and VLP-specific protein enrichment in the final product
- 4.In vivo therapeutic evaluation(in_vivo_validation)
This stage validates that improved purification quality is associated with improved therapeutic outcomes in vivo.
Selection: testing whether chromatographically purified VLPs improve therapeutic outcomes in vivo
Objective: Deploy nanotechnology against COVID-19 across the outbreak-control priorities of prevention, early detection, and treatment.
Why it works: The review organizes nanotechnology applications around the public-health sequence of prevention, early detection, and treatment, matching different nanomaterial functions to each objective.
viral inactivationsensitive detectioncontrolled delivery of therapeuticsnanomaterial engineeringbiosensor developmentpoint-of-care diagnostic engineeringnanocarrier formulation
Stages
- 1.Prevention applications(decision_gate)
The review places prevention first in line with WHO outbreak-control priorities.
Selection: Use nanotechnology to reduce exposure risk through enhanced PPE, antiviral surfaces, and disinfectants.
- 2.Early detection and diagnosis applications(functional_characterization)
The review identifies early detection as a core outbreak-control strategy and maps diagnostic nanotechnologies to that need.
Selection: Use nanoparticle and nanosensor systems for rapid point-of-care and sensitive detection.
- 3.Treatment and therapeutic delivery applications(functional_characterization)
The review places treatment after prevention and diagnosis as the third major strategy.
Selection: Use nanoparticle vaccine and delivery platforms to support treatment efforts and controlled therapeutic delivery.
Objective: Advance gene therapy platforms toward successful clinical implementation by combining editing technologies with delivery optimization and translational risk reduction.
Why it works: The review frames clinical success as depending not only on editor capability but also on systematic resolution of delivery, safety, and manufacturing bottlenecks.
genome editingmitochondrial genome modificationRNA editingepigenetic modulationviral deliverynon-viral deliverypredictive analysisrational vector designpatient stratification
Stages
- 1.Platform and delivery-method selection(library_design)
The review explicitly surveys editing technologies together with their corresponding delivery methodologies, implying that platform choice is coupled to delivery choice early in development.
Selection: Choose among editing platform classes and corresponding delivery methodologies appropriate for the therapeutic application.
- 2.Delivery and efficiency optimization(functional_characterization)
The abstract identifies delivery across physiological barriers and editing efficiency in post-mitotic tissues as major unresolved challenges.
Selection: Optimize delivery across physiological barriers and improve editing efficiency, especially in post-mitotic tissues.
- 3.Safety and manufacturability assessment(confirmatory_validation)
The review states that established technical capability is insufficient without resolving safety and manufacturing bottlenecks.
Selection: Assess long-term safety and manufacturing scalability before clinical implementation.
- 4.Clinical implementation readiness(decision_gate)
The review concludes that successful clinical implementation requires standardized protocols and regulatory frameworks alongside technical resolution of delivery, safety, and manufacturing issues.
Selection: Require standardized patient stratification protocols and robust regulatory frameworks in addition to technical performance.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Target processes
editingmanufacturingtranslationInput: Chemical
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: externally suppliedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: delivery
The abstract states that VLP production uses bacterial, yeast, insect, mammalian, and plant-based expression platforms. It also notes that optimization strategies are needed across these systems.; require expression platforms for production; production platform choice involves advantages, challenges, and optimization strategies; requires use of virus-like particle scaffold systems; platform-level evidence in the abstract does not specify a single VLP design or production system; Use of VLPs in this study depends on downstream purification workflows, including chromatographic processing, to obtain high-quality material. The abstract also frames them as engineered particles derived from MLV or HIV-related systems.; requires purification methods that support product quality and scalability; The abstract does not specify production system, antigen design, or formulation requirements.; requires use as a defined particulate platform in a treatment or vaccine context; The abstract supports only that they function as a delivery methodology paired with gene therapeutic technologies.; requires compatible payload packaging strategy; The abstract specifically places VLP use in the context of integration with mRNA technology.; used in the context of integration with mRNA technology
The abstract does not establish that virus-like particles provide the same selective permeability or pathway encapsulation features highlighted for bacterial microcompartments.; the abstract does not specify cargo-loading rules, permeability, or comparative performance; The abstract does not establish that VLPs provide uniformly strong efficacy across all studies. It explicitly notes wide confidence intervals and variability in efficacy.; wide confidence intervals suggest variability in efficacy across studies; The abstract indicates that VLPs alone do not solve manufacturing and purification bottlenecks. Without adequate purification, product quality and clinical translation remain limited.; clinical translation is hindered by inadequate purification methods; The abstract does not establish diagnostic use, exact delivery behavior, or how they compare quantitatively with LNPs or other carriers.; the abstract does not specify mechanism, payload, or comparative performance; the abstract provides no comparative performance details; The abstract does not establish whether they overcome manufacturing, safety, or tissue-barrier limitations better than alternatives.; the abstract does not specify cargo format, targeting properties, or comparative performance
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2primary paper2025MED
Source 3primary paper2026MED
Source 4review2025MED
Source 5review2025MED
Source 6primary paper2025MED
Source 7review2025MED
Source 8primary paper2026MED
Source 9primary paper2025MED
Ranked Claims
Virus-like particles and virosomes are reviewed as vaccine platforms for SARS-CoV-2, influenza, Newcastle disease virus, malaria, hepatitis, and respiratory syncytial virus, indicating versatility and clinical potential.
The review discusses AAVs, LNPs, lentivirus, and virus-like particles as emerging delivery vehicles for gene editing therapies targeting lipid metabolism in cardiovascular disease.
Emerging delivery vehicles (AAVs, LNPs, lentivirus, virus-like particles) and their translational implications are discussed.
Virosomes are reconstituted viral envelopes that retain functional glycoproteins but lack a nucleocapsid.
Virus-like particles are self-assembled nanostructures composed of viral structural proteins that mimic native virions without carrying genetic material.
Virus-like particle production is examined across bacterial, yeast, insect, mammalian, and plant-based expression platforms, each with distinct advantages, challenges, and optimization strategies.
Virus-like particles and virosomes provide strong immunogenicity and safety by mimicking viral architecture while eliminating the risk of replication.
The review discusses nanoparticle applications including mosaic nanoparticle vaccines, cocktail nanoparticle vaccines, surface-modified targeting strategies, and integration of mRNA technology with virus-like particles.
Nanotechnology-enabled diagnostic approaches in the review include gold nanoparticles, magnetic nanoparticle biosensors, quantum dots, and AI-integrated nanosensors for rapid point-of-care or sensitive detection.
Nanotechnology-enabled prevention approaches in the review include nanofiber-enhanced masks, antiviral surface coatings, and nanoparticle-based disinfectants.
Treatment-oriented nanotechnology approaches in the review include lipid nanoparticle vaccines, virus-like particles, and targeted or controlled therapeutic delivery systems such as polymeric nanocarriers.
Exosomes, virus-like particles, and biomimetic nanostructures are biological nanoparticles with properties that can address key CAR therapy limitations.
Successful clinical implementation requires systematic resolution of manufacturing, safety, and delivery challenges together with standardized patient stratification protocols and robust regulatory frameworks.
Chromatographically purified VLPs have superior protein composition, consistency, and functional delivery compared with VLPs partially purified by conventional ultracentrifugation.
Ultracentrifugation-based purification approaches for VLPs suffer from inconsistent product quality and poor scalability.
These nanoplatforms enable targeted delivery of genetic constructs.
The review covers both viral and non-viral delivery systems, including tissue-specific AAV serotypes, ionizable lipid nanoparticles, virus-like particles, exosome-based delivery, and the SEND system.
Biological nanoparticle platforms facilitate non-viral in vivo CAR cell engineering and streamline the process compared with conventional ex vivo methods.
In vivo studies confirmed improved therapeutic outcomes when chromatographically purified VLPs were used.
Mass spectrometric analysis showed that VLP-specific proteins comprised more than 90% of the final purified product.
VLP-specific proteins in final product 90 %
The chromatographic workflow removes host cell proteins and cell-culture contaminants while improving VLP integrity and biological activity.
In subgroup analysis, viral vector vaccines showed higher protection than other reviewed FMD vaccine platforms, but efficacy estimates were highly variable across studies.
95% confidence interval 0.08-46.65relative risk 1.9 RR
In subgroup analysis, VLP vaccines showed higher protection than other reviewed FMD vaccine platforms, but efficacy estimates were variable across studies.
95% confidence interval 0.97-2.86relative risk 1.66 RR
Peptide vaccines demonstrated moderate efficacy in the reviewed FMD vaccine studies.
95% confidence interval 0.75-1.57relative risk 1.09 RR
A broadly applicable chromatography-based purification strategy improves the purity and therapeutic efficacy of genome-editing VLPs.
Exosomes and biomimetic nanoparticles have versatile cargo capacity for payloads such as mRNA and circular RNA.
Clinical translation of VLP vectors is hindered by inadequate purification methods.
Advanced delivery methods including nanoliposomes, VLPs, and dendrimeric peptides have been linked to enhanced immune responses in FMD vaccine studies.
Dendritic cell-based vaccines provided limited benefit in the reviewed FMD vaccine literature.
These nanoplatforms can mitigate the risk of cytokine release syndrome.
mRNA vaccine design includes mRNA engineering strategies and delivery innovations such as lipid nanoparticles, polymeric nanoparticles, virus-like particles, and needle-free administration technologies.
Despite established technological capabilities, major remaining challenges include manufacturing scalability, long-term safety assessment, delivery across physiological barriers, and optimization of editing efficiency in post-mitotic tissues.
Approval Evidence
10 sources18 linked approval claimsfirst-pass slug virus-like-particles
We discuss the structural and functional diversity of these proteinaceous scaffolds, including self-assembling nanostructures, virus-like particles, and modular interaction systems.
Source:
Emerging delivery vehicles (AAVs, LNPs, lentivirus, virus-like particles) and their translational implications are discussed.
Source:
This review explores virus biomimetic delivery systems, focusing on virus-like particles (VLPs) and virosomes as promising platforms for vaccine and therapeutic development. VLPs are self-assembled nanostructures composed of viral structural proteins that mimic native virions without carrying genetic material.
Source:
Subsequently, we delve into cutting-edge applications of nanoparticles to enhance immune protection, including mosaic and cocktail nanoparticle vaccines, surface-modified targeting strategies, and the integration of mRNA technology with virus-like particles (VLPs).
Source:
Biological nanoparticles, such as exosomes, virus-like particles, and biomimetic nanostructures, possess unique properties that can address these limitations.
Source:
The review encompasses... non-viral delivery systems such as ionizable lipid nanoparticles and virus-like particles...
Source:
delivery innovations such as ... virus-like particles (VLPs)
Source:
supporting treatment efforts through lipid nanoparticle (LNP) vaccines, virus-like particles, and targeted drug delivery systems
Source:
virus-like particles (VLPs) represent a technology of choice in genome editing
Source:
Innovative delivery methods, such as nanoliposomes, virus-like particles (VLPs), and dendrimeric peptides, have been linked to enhanced immune responses.
Source:
application scopesupports
Virus-like particles and virosomes are reviewed as vaccine platforms for SARS-CoV-2, influenza, Newcastle disease virus, malaria, hepatitis, and respiratory syncytial virus, indicating versatility and clinical potential.
Source:
delivery scopesupports
The review discusses AAVs, LNPs, lentivirus, and virus-like particles as emerging delivery vehicles for gene editing therapies targeting lipid metabolism in cardiovascular disease.
Emerging delivery vehicles (AAVs, LNPs, lentivirus, virus-like particles) and their translational implications are discussed.
Source:
platform definitionsupports
Virus-like particles are self-assembled nanostructures composed of viral structural proteins that mimic native virions without carrying genetic material.
Source:
production platform scopesupports
Virus-like particle production is examined across bacterial, yeast, insect, mammalian, and plant-based expression platforms, each with distinct advantages, challenges, and optimization strategies.
Source:
safety immunogenicitysupports
Virus-like particles and virosomes provide strong immunogenicity and safety by mimicking viral architecture while eliminating the risk of replication.
Source:
application scopesupports
The review discusses nanoparticle applications including mosaic nanoparticle vaccines, cocktail nanoparticle vaccines, surface-modified targeting strategies, and integration of mRNA technology with virus-like particles.
Source:
application summarysupports
Treatment-oriented nanotechnology approaches in the review include lipid nanoparticle vaccines, virus-like particles, and targeted or controlled therapeutic delivery systems such as polymeric nanocarriers.
Source:
capabilitysupports
Exosomes, virus-like particles, and biomimetic nanostructures are biological nanoparticles with properties that can address key CAR therapy limitations.
Source:
clinical translation requirementsupports
Successful clinical implementation requires systematic resolution of manufacturing, safety, and delivery challenges together with standardized patient stratification protocols and robust regulatory frameworks.
Source:
comparisonsupports
Chromatographically purified VLPs have superior protein composition, consistency, and functional delivery compared with VLPs partially purified by conventional ultracentrifugation.
Source:
comparisonsupports
Ultracentrifugation-based purification approaches for VLPs suffer from inconsistent product quality and poor scalability.
Source:
delivery landscapesupports
The review covers both viral and non-viral delivery systems, including tissue-specific AAV serotypes, ionizable lipid nanoparticles, virus-like particles, exosome-based delivery, and the SEND system.
Source:
in vivo outcomesupports
In vivo studies confirmed improved therapeutic outcomes when chromatographically purified VLPs were used.
Source:
meta analysis resultsupports
In subgroup analysis, VLP vaccines showed higher protection than other reviewed FMD vaccine platforms, but efficacy estimates were variable across studies.
Source:
problem statementsupports
Clinical translation of VLP vectors is hindered by inadequate purification methods.
Source:
review conclusionsupports
Advanced delivery methods including nanoliposomes, VLPs, and dendrimeric peptides have been linked to enhanced immune responses in FMD vaccine studies.
Source:
scope statementsupports
mRNA vaccine design includes mRNA engineering strategies and delivery innovations such as lipid nanoparticles, polymeric nanoparticles, virus-like particles, and needle-free administration technologies.
Source:
translational limitationsupports
Despite established technological capabilities, major remaining challenges include manufacturing scalability, long-term safety assessment, delivery across physiological barriers, and optimization of editing efficiency in post-mitotic tissues.
Source:
Comparisons
Source-stated alternatives
The review contrasts VLPs with virosomes as another principal virus biomimetic delivery platform.; The abstract contrasts virus-like particles with AAVs, LNPs, and lentivirus.; The abstract contrasts them with self-assembling nanostructures, modular interaction systems, and especially bacterial microcompartments.; The review compares VLPs with peptide-based, viral vector, and dendritic cell-based vaccines. Nanoliposomes and dendrimeric peptides are also mentioned as innovative delivery-related approaches.; The abstract contrasts chromatographically purified VLPs with VLPs partially purified by conventional ultracentrifugation methods. Ultracentrifugation is presented as the incumbent but less scalable and less consistent approach.; Nearby alternatives named in the abstract include lipid nanoparticles, targeted drug delivery systems, and polymeric nanocarriers.; The abstract places VLPs alongside lipid nanoparticles, polymeric nanoparticles, and needle-free administration technologies.; The review places virus-like particles alongside AAV, ionizable LNPs, exosome-based delivery, and SEND.; The abstract mentions exosomes and biomimetic nanostructures alongside virus-like particles.
Source:
The review contrasts VLPs with virosomes as another principal virus biomimetic delivery platform.
Source:
The abstract contrasts virus-like particles with AAVs, LNPs, and lentivirus.
Source:
The abstract contrasts them with self-assembling nanostructures, modular interaction systems, and especially bacterial microcompartments.
Source:
The review compares VLPs with peptide-based, viral vector, and dendritic cell-based vaccines. Nanoliposomes and dendrimeric peptides are also mentioned as innovative delivery-related approaches.
Source:
The abstract contrasts chromatographically purified VLPs with VLPs partially purified by conventional ultracentrifugation methods. Ultracentrifugation is presented as the incumbent but less scalable and less consistent approach.
Source:
Nearby alternatives named in the abstract include lipid nanoparticles, targeted drug delivery systems, and polymeric nanocarriers.
Source:
The abstract places VLPs alongside lipid nanoparticles, polymeric nanoparticles, and needle-free administration technologies.
Source:
The review places virus-like particles alongside AAV, ionizable LNPs, exosome-based delivery, and SEND.
Source:
The abstract mentions exosomes and biomimetic nanostructures alongside virus-like particles.
Source-backed strengths
mimic native virions; lack genetic material; strong immunogenicity; safety through elimination of replication risk; included as a distinct proteinaceous scaffold class in the review; linked to enhanced immune responses; showed higher protection in subgroup analysis than other platforms reviewed; robust cell-entry capacity; explicitly highlighted as part of treatment efforts; presented as an emerging delivery innovation; highlighted as part of advanced delivery systems; presented as part of cutting-edge nanoparticle applications to enhance immune protection
Source:
mimic native virions
Source:
lack genetic material
Source:
strong immunogenicity
Source:
safety through elimination of replication risk
Source:
included as a distinct proteinaceous scaffold class in the review
Source:
linked to enhanced immune responses
Source:
showed higher protection in subgroup analysis than other platforms reviewed
Source:
robust cell-entry capacity
Source:
explicitly highlighted as part of treatment efforts
Source:
presented as an emerging delivery innovation
Source:
highlighted as part of advanced delivery systems
Source:
presented as part of cutting-edge nanoparticle applications to enhance immune protection
Compared with AAV-based viral vectors
The abstract contrasts virus-like particles with AAVs, LNPs, and lentivirus.
Shared frame: source-stated alternative in extracted literature
Strengths here: mimic native virions; lack genetic material; strong immunogenicity.
Relative tradeoffs: the abstract does not specify cargo-loading rules, permeability, or comparative performance; wide confidence intervals suggest variability in efficacy across studies; clinical translation is hindered by inadequate purification methods.
Source:
The abstract contrasts virus-like particles with AAVs, LNPs, and lentivirus.
Compared with Adeno-associated virus
The abstract contrasts virus-like particles with AAVs, LNPs, and lentivirus.
Shared frame: source-stated alternative in extracted literature
Strengths here: mimic native virions; lack genetic material; strong immunogenicity.
Relative tradeoffs: the abstract does not specify cargo-loading rules, permeability, or comparative performance; wide confidence intervals suggest variability in efficacy across studies; clinical translation is hindered by inadequate purification methods.
Source:
The abstract contrasts virus-like particles with AAVs, LNPs, and lentivirus.
Compared with dendrimeric peptides
The review compares VLPs with peptide-based, viral vector, and dendritic cell-based vaccines. Nanoliposomes and dendrimeric peptides are also mentioned as innovative delivery-related approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: mimic native virions; lack genetic material; strong immunogenicity.
Relative tradeoffs: the abstract does not specify cargo-loading rules, permeability, or comparative performance; wide confidence intervals suggest variability in efficacy across studies; clinical translation is hindered by inadequate purification methods.
Source:
The review compares VLPs with peptide-based, viral vector, and dendritic cell-based vaccines. Nanoliposomes and dendrimeric peptides are also mentioned as innovative delivery-related approaches.
Compared with dengue enveloped viral-like particle vaccine prototype
The review contrasts VLPs with virosomes as another principal virus biomimetic delivery platform.; The review compares VLPs with peptide-based, viral vector, and dendritic cell-based vaccines. Nanoliposomes and dendrimeric peptides are also mentioned as innovative delivery-related approaches.; The abstract contrasts chromatographically purified VLPs with VLPs partially purified by conventional ultracentrifugation methods. Ultracentrifugation is presented as the incumbent but less scalable and less consistent approach.; The abstract places VLPs alongside lipid nanoparticles, polymeric nanoparticles, and needle-free administration technologies.
Shared frame: source-stated alternative in extracted literature
Strengths here: mimic native virions; lack genetic material; strong immunogenicity.
Relative tradeoffs: the abstract does not specify cargo-loading rules, permeability, or comparative performance; wide confidence intervals suggest variability in efficacy across studies; clinical translation is hindered by inadequate purification methods.
Source:
The review contrasts VLPs with virosomes as another principal virus biomimetic delivery platform.
Source:
The review compares VLPs with peptide-based, viral vector, and dendritic cell-based vaccines. Nanoliposomes and dendrimeric peptides are also mentioned as innovative delivery-related approaches.
Source:
The abstract contrasts chromatographically purified VLPs with VLPs partially purified by conventional ultracentrifugation methods. Ultracentrifugation is presented as the incumbent but less scalable and less consistent approach.
Source:
The abstract places VLPs alongside lipid nanoparticles, polymeric nanoparticles, and needle-free administration technologies.
Compared with Exosomes
The review places virus-like particles alongside AAV, ionizable LNPs, exosome-based delivery, and SEND.; The abstract mentions exosomes and biomimetic nanostructures alongside virus-like particles.
Shared frame: source-stated alternative in extracted literature
Strengths here: mimic native virions; lack genetic material; strong immunogenicity.
Relative tradeoffs: the abstract does not specify cargo-loading rules, permeability, or comparative performance; wide confidence intervals suggest variability in efficacy across studies; clinical translation is hindered by inadequate purification methods.
Source:
The review places virus-like particles alongside AAV, ionizable LNPs, exosome-based delivery, and SEND.
Source:
The abstract mentions exosomes and biomimetic nanostructures alongside virus-like particles.
Compared with HIV-1 Gag-based virus-like particles
The review contrasts VLPs with virosomes as another principal virus biomimetic delivery platform.; The review compares VLPs with peptide-based, viral vector, and dendritic cell-based vaccines. Nanoliposomes and dendrimeric peptides are also mentioned as innovative delivery-related approaches.; The abstract contrasts chromatographically purified VLPs with VLPs partially purified by conventional ultracentrifugation methods. Ultracentrifugation is presented as the incumbent but less scalable and less consistent approach.; The abstract places VLPs alongside lipid nanoparticles, polymeric nanoparticles, and needle-free administration technologies.
Shared frame: source-stated alternative in extracted literature
Strengths here: mimic native virions; lack genetic material; strong immunogenicity.
Relative tradeoffs: the abstract does not specify cargo-loading rules, permeability, or comparative performance; wide confidence intervals suggest variability in efficacy across studies; clinical translation is hindered by inadequate purification methods.
Source:
The review contrasts VLPs with virosomes as another principal virus biomimetic delivery platform.
Source:
The review compares VLPs with peptide-based, viral vector, and dendritic cell-based vaccines. Nanoliposomes and dendrimeric peptides are also mentioned as innovative delivery-related approaches.
Source:
The abstract contrasts chromatographically purified VLPs with VLPs partially purified by conventional ultracentrifugation methods. Ultracentrifugation is presented as the incumbent but less scalable and less consistent approach.
Source:
The abstract places VLPs alongside lipid nanoparticles, polymeric nanoparticles, and needle-free administration technologies.
Compared with lentivirus
The abstract contrasts virus-like particles with AAVs, LNPs, and lentivirus.
Shared frame: source-stated alternative in extracted literature
Strengths here: mimic native virions; lack genetic material; strong immunogenicity.
Relative tradeoffs: the abstract does not specify cargo-loading rules, permeability, or comparative performance; wide confidence intervals suggest variability in efficacy across studies; clinical translation is hindered by inadequate purification methods.
Source:
The abstract contrasts virus-like particles with AAVs, LNPs, and lentivirus.
Compared with lipid nanoparticle
Nearby alternatives named in the abstract include lipid nanoparticles, targeted drug delivery systems, and polymeric nanocarriers.; The abstract places VLPs alongside lipid nanoparticles, polymeric nanoparticles, and needle-free administration technologies.
Shared frame: source-stated alternative in extracted literature
Strengths here: mimic native virions; lack genetic material; strong immunogenicity.
Relative tradeoffs: the abstract does not specify cargo-loading rules, permeability, or comparative performance; wide confidence intervals suggest variability in efficacy across studies; clinical translation is hindered by inadequate purification methods.
Source:
Nearby alternatives named in the abstract include lipid nanoparticles, targeted drug delivery systems, and polymeric nanocarriers.
Source:
The abstract places VLPs alongside lipid nanoparticles, polymeric nanoparticles, and needle-free administration technologies.
Compared with lipid nanoparticles
The abstract contrasts virus-like particles with AAVs, LNPs, and lentivirus.; Nearby alternatives named in the abstract include lipid nanoparticles, targeted drug delivery systems, and polymeric nanocarriers.; The abstract places VLPs alongside lipid nanoparticles, polymeric nanoparticles, and needle-free administration technologies.; The review places virus-like particles alongside AAV, ionizable LNPs, exosome-based delivery, and SEND.
Shared frame: source-stated alternative in extracted literature
Strengths here: mimic native virions; lack genetic material; strong immunogenicity.
Relative tradeoffs: the abstract does not specify cargo-loading rules, permeability, or comparative performance; wide confidence intervals suggest variability in efficacy across studies; clinical translation is hindered by inadequate purification methods.
Source:
The abstract contrasts virus-like particles with AAVs, LNPs, and lentivirus.
Source:
Nearby alternatives named in the abstract include lipid nanoparticles, targeted drug delivery systems, and polymeric nanocarriers.
Source:
The abstract places VLPs alongside lipid nanoparticles, polymeric nanoparticles, and needle-free administration technologies.
Source:
The review places virus-like particles alongside AAV, ionizable LNPs, exosome-based delivery, and SEND.
Compared with LNP
Nearby alternatives named in the abstract include lipid nanoparticles, targeted drug delivery systems, and polymeric nanocarriers.; The abstract places VLPs alongside lipid nanoparticles, polymeric nanoparticles, and needle-free administration technologies.
Shared frame: source-stated alternative in extracted literature
Strengths here: mimic native virions; lack genetic material; strong immunogenicity.
Relative tradeoffs: the abstract does not specify cargo-loading rules, permeability, or comparative performance; wide confidence intervals suggest variability in efficacy across studies; clinical translation is hindered by inadequate purification methods.
Source:
Nearby alternatives named in the abstract include lipid nanoparticles, targeted drug delivery systems, and polymeric nanocarriers.
Source:
The abstract places VLPs alongside lipid nanoparticles, polymeric nanoparticles, and needle-free administration technologies.
Compared with mRNA-lipid nanoparticles
The abstract contrasts virus-like particles with AAVs, LNPs, and lentivirus.; The review places virus-like particles alongside AAV, ionizable LNPs, exosome-based delivery, and SEND.
Shared frame: source-stated alternative in extracted literature
Strengths here: mimic native virions; lack genetic material; strong immunogenicity.
Relative tradeoffs: the abstract does not specify cargo-loading rules, permeability, or comparative performance; wide confidence intervals suggest variability in efficacy across studies; clinical translation is hindered by inadequate purification methods.
Source:
The abstract contrasts virus-like particles with AAVs, LNPs, and lentivirus.
Source:
The review places virus-like particles alongside AAV, ionizable LNPs, exosome-based delivery, and SEND.
Compared with mRNA-loaded lipid nanoparticles
The abstract contrasts virus-like particles with AAVs, LNPs, and lentivirus.; The review places virus-like particles alongside AAV, ionizable LNPs, exosome-based delivery, and SEND.
Shared frame: source-stated alternative in extracted literature
Strengths here: mimic native virions; lack genetic material; strong immunogenicity.
Relative tradeoffs: the abstract does not specify cargo-loading rules, permeability, or comparative performance; wide confidence intervals suggest variability in efficacy across studies; clinical translation is hindered by inadequate purification methods.
Source:
The abstract contrasts virus-like particles with AAVs, LNPs, and lentivirus.
Source:
The review places virus-like particles alongside AAV, ionizable LNPs, exosome-based delivery, and SEND.
Compared with virus-like particle vaccine platform
The abstract contrasts virus-like particles with AAVs, LNPs, and lentivirus.; The review places virus-like particles alongside AAV, ionizable LNPs, exosome-based delivery, and SEND.; The abstract mentions exosomes and biomimetic nanostructures alongside virus-like particles.
Shared frame: source-stated alternative in extracted literature
Strengths here: mimic native virions; lack genetic material; strong immunogenicity.
Relative tradeoffs: the abstract does not specify cargo-loading rules, permeability, or comparative performance; wide confidence intervals suggest variability in efficacy across studies; clinical translation is hindered by inadequate purification methods.
Source:
The abstract contrasts virus-like particles with AAVs, LNPs, and lentivirus.
Source:
The review places virus-like particles alongside AAV, ionizable LNPs, exosome-based delivery, and SEND.
Source:
The abstract mentions exosomes and biomimetic nanostructures alongside virus-like particles.
Ranked Citations
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.